GLP-1 may slow biological aging

A new study published in Nature Communications provides the first randomized, placebo-controlled clinical evidence that semaglutide (Ozempic/Wegovy) slows biological aging markers in adults with HIV, reducing the pace of aging by 9% across multiple epigenetic clocks. Researchers attribute this effect to the drug's ability to reduce inflammation, metabolic stress, and visceral fat accumulation, which are key drivers of accelerated aging in HIV-positive individuals.